ANGLE PLC (LON:AGL, OTCQX:ANPCY) is part of a Europe-wide consortium that will set the standards for using blood-based markers to identify cancer.
The AIM-listed company will contribute its Parsortix technology, which harvests circulation tumour cells (CTC) that identify the presence and particular strain of the killer disease.
The CANCER-ID programme in which it is taking part will assess whether the ANGLE device should provide the standard method of harvesting CTCs.
Running until 2020, an initial evaluation will be followed by a clinical phase to establish the use of liquid biopsies in treating lung and breast cancer.
This is intended to provide clinical evidence to support the adoption of liquid biopsy in routine cancer care.
CANCER-ID is backed by €14mln of funding and involves 38 companies and institutions from 13 countries across Europe, including German giant Bayer and Italy’s Menarini Silicon Biosystems.
Andrew Newland, ANGLE’s founder and chief executive, said: “We are delighted to be part of this programme as it offers the Parsortix system the potential to be specified as a standard CTC harvesting system for clinical use in patients with lung cancer and breast cancer in Europe, with the opportunity for collaboration with multiple downstream analysis companies."